Jenburkt Pharmaceuticals Limited

Equities

JENBURPH6

INE354A01013

Pharmaceuticals

Market Closed - Bombay S.E. 03:30:57 04/07/2024 pm IST 5-day change 1st Jan Change
878.4 INR -0.02% Intraday chart for Jenburkt Pharmaceuticals Limited +1.53% +29.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Jenburkt Pharmaceuticals Limited Announces Board Retirements CI
Jenburkt Pharmaceuticals Limited Announces Dividend CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Jenburkt Pharmaceuticals Limited Appoints Sumit Ajaybhai Thakkar as A Non-Executive and Independent Director CI
Jenburkt Pharmaceuticals Limited Appoints Sumit Ajaybhai Thakkar as Non-Executive Independent Director CI
Jenburkt Pharmaceuticals Limited Approves Dividend for the Financial Year Ended 31 March, 2023 CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Jenburkt Pharmaceuticals Limited Approves Dividend CI
Tranche Update on Jenburkt Pharmaceuticals Limited's Equity Buyback Plan announced on December 1, 2022. CI
Jenburkt Pharmaceuticals Limited's Equity Buyback announced on December 1, 2022, has closed with repurchase of 176,078 shares, representing 3.84% for INR 114.24 million. CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Jenburkt Pharmaceuticals Limited announces an Equity Buyback for INR 116 million worth of its shares. CI
Jenburkt Pharmaceuticals Limited authorizes a Buyback Plan. CI
Jenburkt Pharmaceuticals Board to Consider Share Buyback MT
Jenburkt Pharmaceuticals Limited's Board intends to launch an Equity Buyback on December 1, 2022. CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Jenburkt Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022 CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Jenburkt Pharmaceuticals Limited Approves Dividend CI
Jenburkt Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Chart Jenburkt Pharmaceuticals Limited
More charts
Jenburkt Pharmaceuticals Limited is an India-based company that is engaged in the business of manufacturing, producing, developing and marketing a range of branded pharmaceuticals and health care products. The Company offers pharmaceutical products for various therapeutic areas, analgesic and antipyretics anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer division, cough and cold, muscle relaxants neuropathic pain, nutraceuticals and pain management. The Company's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets and others. The Company's manufacturing plant is located in Sihor-Gujarat. The Company's products are exported to approximately 13 countries globally.
More about the company
  1. Stock Market
  2. Equities
  3. JENBURPH6 Stock
  4. News Jenburkt Pharmaceuticals Limited
  5. Jenburkt Pharmaceuticals Board to Consider Share Buyback